Bengaluru: Eli Lilly and Hong Kong-listed Laekna will collaborate to develop an experimental obesity drug that aims to help ...

Vyriad announced a collaboration with Novartis to develop in vivo CAR T therapies. Eli Lilly teamed up with Chinese biotech ...

Eli Lilly has partnered with Laekna to advance LAE102, an antibody targeting the ActRIIA receptor, for obesity and muscle ...

Lilly will provide the funding and expertise to advance Laekna’s LAE102, a first-in-class monoclonal antibody targeting the ...

Laekna, Inc. (HK:2105) has released an update.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top Wall Street ...

LAEKNA-B (02105.HK) announced a share placing immediately after a 48% share surge yesterday (20th). Today (21st), it opened ...

Eli Lilly and Hong Kong-listed Laekna will collaborate to develop an experimental obesity drug that aims to help patients ...

Eli Lilly (LLY) partners with Laekna Therapeutics to develop an obesity therapy that avoids muscle loss. Read more here.

Laekna, Inc. (2105.HK) (“Laekna”), a global biotech company focused on novel drug development for metabolic and cancer ...

Eli Lilly and Company (NYSE: LLY) announced today that it has elected Jon Moeller as a new member of its board of directors ...

Laekna, Inc. (HK:2105) has released an update.Don't Miss out on Research Tools:Discover the latest stocks recommended by top Wall Street ...

LAEKNA-B (02105.HK) opened 0.94% lower today (20th) but managed to make a rebound, peaking at $14.54 with an uptick of 37%.